Table 4.
Average discounted costs per patient in the target population.
| Costs | Oncotype DX® test | SoC | Incremental |
|---|---|---|---|
| Test | €1,850 | €0 | €1,850 |
| Adjuvant treatments1 | €2,454 | €3,559 | −€1,106 |
| Transportation | €931 | €1,388 | −€457 |
| Sick leave due to CT | €2,032 | €5,306 | −€3,274 |
| Recurrence-free | €26,160 | €25,532 | €628 |
| Distant recurrence | €28,413 | €28,705 | −€292 |
| AML | €453 | €1,007 | −€553 |
| CHF | €1,827 | €2,065 | −€239 |
| End of life | €2,434 | €2,404 | €31 |
| Total | €66,554 | €69,966 | −€3,412 |
AML, acute myeloid leukemia; CHF, chronic heart failure; CT, chemotherapy; SoC, standard of care.
1 ET only or ET+CT.